Dr. Anton (Tony) Hoos is set to become the new Head of R&D and Medical Affairs, Chief Medical Officer, and member of the Sobi Executive Committee. His impressive three-decade-long career in the global pharmaceutical industry has included positions at Amgen, GSK, and Aventis, and most recently, a board position at Patient Focused Medicine Development, a non-profit dedicated to bringing the voice of patients into drug development. Based in Basel, Switzerland, Tony will report to CEO Guido Oelkers, succeeding the retiring Anders Ullman, M.D., Ph.D.
Guido Oelkers: “We are delighted to welcome Tony to lead our R&D and medical activities. With his deep knowledge and understanding of patient engagement, Tony is sure to bring invaluable insights and perspectives to Sobi. We thank Anders for his hard work and dedication to the organisation over the past year, having successfully implemented transformative changes in the way the function works.”
Sobi’s R&D teams span the globe; with major research & development centers in Stockholm, Sweden and Basel, Switzerland, and satellite teams in Durham, North Carolina, USA and Tokyo, Japan – there’s a total of 215 talented professionals working hard to revolutionize the industry. From bioanalytics and biostatistics to clinical science, late-stage program development, medical writing, regulatory affairs, pharmacovigilance and portfolio management – Sobi’s research & development is truly diverse and far-reaching.